Market Overview - On March 20, US stock indices experienced slight declines, with the Dow Jones down 0.03%, S&P 500 down 0.22%, and Nasdaq down 0.33% [1] - Chinese concept stocks saw a significant drop, with the Nasdaq Golden Dragon China Index falling 3.84%, marking the largest single-day decline since February 25 [2] Company Performance - Plus Therapeutics experienced a dramatic increase of 170.06% in stock price, with a trading volume of 35.8 million shares, following the announcement of its lung cancer treatment receiving "orphan drug" designation from the FDA [2][3] - Pinduoduo's stock rose 3.97% despite a general downturn in Chinese stocks, reporting a total revenue of 393.8361 billion yuan for 2024, a 59% year-on-year increase, and a net profit of 112.435 billion yuan, up 87% [5][6] Financial Results - Nike reported a revenue of $11.269 billion for Q3 of FY2025, a decline of over 9% year-on-year, with a net profit of $794 million, down over 32% [8] - Micron Technology's adjusted revenue for Q2 was $8.05 billion, a 38% year-on-year increase, exceeding analyst expectations [8] Economic Outlook - Jeffrey Gundlach, co-founder of DoubleLine Capital, indicated a 50% to 60% chance of the US economy entering a recession, citing concerns over tariffs and inflation stability [9]